Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

Researchers suggest people taking Ozempic and similar drugs may face double the risk of developing wet age-related macular ...

Instant ramen maker Nissin Foods is leveraging the buzz around GLP-1s to launch in the US a trio of decadent tasting frozen ...